Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Blood neurofilament light levels segregate treatment effects in multiple sclerosis.

Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F.

Neurology. 2020 Feb 11. pii: 10.1212/WNL.0000000000009097. doi: 10.1212/WNL.0000000000009097. [Epub ahead of print]

PMID:
32047070
2.

[Patient monitoring 4.0].

Kieseier BC, Bauer M.

Nervenarzt. 2019 Dec;90(12):1205-1206. doi: 10.1007/s00115-019-00823-w. German. No abstract available.

PMID:
31807830
3.

Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.

Pellegrini F, Copetti M, Sormani MP, Bovis F, de Moor C, Debray TP, Kieseier BC.

Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343. [Epub ahead of print]

PMID:
31686590
4.

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, Kappos L, Rudick RA, Goyal J.

Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613. [Epub ahead of print]

PMID:
31680621
5.

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.

Pellegrini F, Copetti M, Bovis F, Cheng D, Hyde R, de Moor C, Kieseier BC, Sormani MP.

Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513. [Epub ahead of print]

PMID:
31144577
6.

Differential impact of pure glyphosate and glyphosate-based herbicide in a model of peripheral nervous system myelination.

Szepanowski F, Szepanowski LP, Mausberg AK, Albrecht P, Kleinschnitz C, Kieseier BC, Stettner M.

Acta Neuropathol. 2018 Dec;136(6):979-982. doi: 10.1007/s00401-018-1938-4. Epub 2018 Nov 16. No abstract available.

PMID:
30446820
7.

Immune-mediated neuropathies.

Kieseier BC, Mathey EK, Sommer C, Hartung HP.

Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Review.

PMID:
30310069
8.

Trapped in the epineurium: early entry into the endoneurium is restricted to neuritogenic T cells in experimental autoimmune neuritis.

Mausberg AK, Szepanowski F, Odoardi F, Flügel A, Kleinschnitz C, Stettner M, Kieseier BC.

J Neuroinflammation. 2018 Aug 1;15(1):217. doi: 10.1186/s12974-018-1259-5.

9.

Progress in Recognizing and Treating Polyneuropathy.

Kieseier BC, Hartung HP.

Dtsch Arztebl Int. 2018 Feb 9;115(6):81-82. doi: 10.3238/arztebl.2018.0081. No abstract available.

10.

Novel pathomechanisms in inflammatory neuropathies.

Schafflick D, Kieseier BC, Wiendl H, Meyer Zu Horste G.

J Neuroinflammation. 2017 Nov 28;14(1):232. doi: 10.1186/s12974-017-1001-8. Review.

11.

Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA1 signaling.

Szepanowski F, Szepanowski LP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M.

Neurosci Lett. 2018 Jan 1;662:136-141. doi: 10.1016/j.neulet.2017.10.023. Epub 2017 Oct 16.

PMID:
29051083
12.

Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II.

Hartlehnert M, Derksen A, Hagenacker T, Kindermann D, Schäfers M, Pawlak M, Kieseier BC, Meyer Zu Horste G.

Sci Rep. 2017 Oct 2;7(1):12518. doi: 10.1038/s41598-017-12744-2.

13.

CIDP and other inflammatory neuropathies in diabetes - diagnosis and management.

Rajabally YA, Stettner M, Kieseier BC, Hartung HP, Malik RA.

Nat Rev Neurol. 2017 Oct;13(10):599-611. doi: 10.1038/nrneurol.2017.123. Epub 2017 Sep 15. Review.

PMID:
28914883
14.

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C.

Front Neurol. 2017 Jul 6;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017.

15.

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.

Scott TF, Kieseier BC, Newsome SD, Arnold DL, You X, Hung S, Sperling B.

Mult Scler J Exp Transl Clin. 2016 Nov 15;2:2055217316676644. doi: 10.1177/2055217316676644. eCollection 2016 Jan-Dec.

16.

Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.

Newsome SD, Kieseier BC, Liu S, You X, Kinter E, Hung S, Sperling B.

Ther Adv Neurol Disord. 2017 Jan;10(1):41-50. doi: 10.1177/1756285616676065. Epub 2016 Nov 16.

17.

The Role of Peripheral Myelin Protein 2 in Remyelination.

Stettner M, Zenker J, Klingler F, Szepanowski F, Hartung HP, Mausberg AK, Kleinschnitz C, Chrast R, Kieseier BC.

Cell Mol Neurobiol. 2018 Mar;38(2):487-496. doi: 10.1007/s10571-017-0494-0. Epub 2017 Apr 26.

PMID:
28447247
18.
19.

Targeting lysophospholipid signaling as a therapeutic approach towards improved peripheral nerve regeneration.

Szepanowski F, Kieseier BC.

Neural Regen Res. 2016 Nov;11(11):1754-1755. doi: 10.4103/1673-5374.194720. No abstract available.

20.

Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway.

Szepanowski F, Donaldson DM, Hartung HP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M.

Acta Neuropathol. 2017 Mar;133(3):489-491. doi: 10.1007/s00401-017-1676-z. Epub 2017 Jan 20. No abstract available.

PMID:
28108787
21.

Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis.

Meyer Zu Horste G, Cordes S, Pfaff J, Mathys C, Mausberg AK, Bendszus M, Pham M, Hartung HP, Kieseier BC.

PLoS One. 2016 Oct 6;11(10):e0164099. doi: 10.1371/journal.pone.0164099. eCollection 2016.

22.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.

Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.

PMID:
27543447
23.

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Leussink VI, Hartung HP, Kieseier BC, Stettner M.

Ther Adv Neurol Disord. 2016 Jul;9(4):336-43. doi: 10.1177/1756285616641583. Epub 2016 Apr 6. Review.

24.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M.

Ther Adv Neurol Disord. 2016 Jul;9(4):239-49. doi: 10.1177/1756285616633967. Epub 2016 Mar 10.

25.

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Newsome SD, Kieseier BC, Arnold DL, Shang S, Liu S, Hung S, Sabatella G.

J Neurol. 2016 Sep;263(9):1778-87. doi: 10.1007/s00415-016-8182-4. Epub 2016 Jun 17.

26.

Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling.

Szepanowski F, Derksen A, Steiner I, Meyer Zu Hörste G, Daldrup T, Hartung HP, Kieseier BC.

J Neuroinflammation. 2016 Jun 10;13(1):143. doi: 10.1186/s12974-016-0612-9.

27.

Alteration of the cytokine signature by various TLR ligands in different T cell populations in MOG37-50 and MOG35-55-induced EAE in C57BL/6 mice.

Steckner C, Weber A, Mausberg AK, Heininger M, Opdenhövel F, Kieseier BC, Hartung HP, Hofstetter HH.

Clin Immunol. 2016 Sep;170:22-30. doi: 10.1016/j.clim.2016.05.008. Epub 2016 May 24.

PMID:
27233983
28.

Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.

Buerth C, Mausberg AK, Heininger MK, Hartung HP, Kieseier BC, Ernst JF.

PLoS One. 2016 May 9;11(5):e0155082. doi: 10.1371/journal.pone.0155082. eCollection 2016.

29.

Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Merkies IS, Kieseier BC.

Eur Neurol. 2016;75(3-4):199-206. doi: 10.1159/000445347. Epub 2016 Apr 15.

30.

Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'.

Leussink VI, Hartung HP, Stüve O, Kieseier BC.

J Neurol. 2016 May;263(5):1027-1028. doi: 10.1007/s00415-016-8110-7. Epub 2016 Apr 8. No abstract available.

PMID:
27060083
31.

Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes.

Weber A, Zimmermann C, Mausberg AK, Dehmel T, Kieseier BC, Hartung HP, Hofstetter HH.

Infect Immun. 2016 Apr 22;84(5):1413-1423. doi: 10.1128/IAI.00905-15. Print 2016 May.

32.

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.

Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, Hartung HP, Malik RA, Kieseier BC.

Ann Clin Transl Neurol. 2015 Dec 28;3(2):88-100. doi: 10.1002/acn3.275. eCollection 2016 Feb.

33.

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK; GRAID investigators.

J Neuroimmune Pharmacol. 2016 Mar;11(1):1-8. doi: 10.1007/s11481-015-9646-5. Epub 2015 Nov 20.

PMID:
26589235
34.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
35.

Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System.

Meyer zu Horste G, Derksen A, Stassart R, Szepanowski F, Thanos M, Stettner M, Boettcher C, Lehmann HC, Hartung HP, Kieseier BC.

J Neuropathol Exp Neurol. 2015 Nov;74(11):1077-85. doi: 10.1097/NEN.0000000000000253.

PMID:
26426268
36.

Multiple sclerosis--a dynamic field with a need for excellent education.

Kieseier BC.

Eur J Neurol. 2015 Oct;22 Suppl 2:1-2. doi: 10.1111/ene.12802. No abstract available.

PMID:
26374507
37.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
38.

Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier BC.

Brain Behav. 2015 Aug;5(8):e00326. doi: 10.1002/brb3.326. Epub 2015 May 29.

39.

Optimizing therapy early in multiple sclerosis: An evidence-based view.

Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC.

Mult Scler Relat Disord. 2015 Sep;4(5):460-469. doi: 10.1016/j.msard.2015.07.007. Epub 2015 Jul 17. Review.

40.

Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system.

Kieseier BC, Wiendl H.

Acta Neuropathol. 2015 Aug;130(2):297-8. doi: 10.1007/s00401-015-1457-5. Epub 2015 Jun 30. No abstract available.

PMID:
26123982
41.

Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.

Kieseier BC, Benamor M.

Neurol Ther. 2014 Nov 20;3(2):133-8. doi: 10.1007/s40120-014-0020-y. eCollection 2014 Dec.

42.

[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Leussink VI, Warnke C, Tackenberg B, Wiendl H, Kieseier BC.

Nervenarzt. 2015 Apr;86(4):483-90. doi: 10.1007/s00115-015-4287-8. German.

PMID:
25833401
43.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755. Review.

PMID:
25800129
44.

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L.

Ann Clin Transl Neurol. 2015 Feb;2(2):119-30. doi: 10.1002/acn3.155. Epub 2015 Jan 16.

45.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
46.

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O.

Ann Clin Transl Neurol. 2015 Jan;2(1):43-55. doi: 10.1002/acn3.152. Epub 2014 Dec 5.

47.

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.

Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC.

Ther Adv Neurol Disord. 2015 Jan;8(1):3-13. doi: 10.1177/1756285614560733.

48.

Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.

Haas J, Schwarz A, Korporal-Kunke M, Jarius S, Wiendl H, Kieseier BC, Wildemann B.

Mult Scler. 2015 Oct;21(12):1521-32. doi: 10.1177/1352458514564589. Epub 2015 Jan 12.

PMID:
25583847
49.

Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.

Kim SH, Hyun JW, Jeong IH, Joung A, Yeon JL, Dehmel T, Adams O, Kieseier BC, Kim HJ.

J Neurol. 2015 Mar;262(3):696-700. doi: 10.1007/s00415-014-7629-8. Epub 2015 Jan 6.

PMID:
25559683
50.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S.

BMC Neurol. 2014 Dec 31;14:240. doi: 10.1186/s12883-014-0240-x.

Supplemental Content

Loading ...
Support Center